$3.20
+0.08 (+2.56%)
Open$3.13
Previous Close$3.12
Day High$3.25
Day Low$3.12
52W High$13.99
52W Low$2.61
Volume—
Avg Volume736.2K
Market Cap295.62M
P/E Ratio—
EPS$-0.46
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+832.8% upside
Current
$3.20
$3.20
Target
$29.85
$29.85
$17.55
$29.85 avg
$40.51
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 62.53M | 56.87M | 56.55M |
| Net Income | 10.24M | 9.50M | 10.72M |
| Profit Margin | 16.4% | 16.7% | 19.0% |
| EBITDA | 18.97M | 15.63M | 16.61M |
| Free Cash Flow | 7.70M | 5.60M | 6.46M |
| Rev Growth | +23.0% | -7.3% | -7.0% |
| Debt/Equity | 0.80 | 0.99 | 0.76 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |